The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 626-634

  Oxlade, O ^a   Falzon, D ^b   Menzies, D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cost effectiveness; Drug resistance; Drug susceptibility testing; Modelling; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT INDICATION; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HIV INFECTIONS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; QUALITY-ADJUSTED LIFE YEARS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84860344660     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00065311     Document Type: Article

References (30)

1. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/ 2010.3. Geneva, World Health Organization, 2010.
2. Anti-Tuberculosis Drug Resistance in the World. Report No. 4. WHO/HTM/TB/2008.394. Geneva, World Health Organization, 2008.
3. Mak A, Thomas A, Del Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312.
4. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
5. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatmnet and/or with mono-resistance to isoniazid: a systematic review and metaanalysis. PLoS Med 2009; 6: e1000150.
6. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581. (Pubitemid 29336573)
7. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
8. Management of Tuberculosis: A Guide to the Essentials of Good Practice. 6th Edn. Paris, International Union Against Tuberculosis and Lung Disease, 2010.
9. Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and metaanalysis. Ann Intern Med 2008; 149: 123-134. (Pubitemid 352008599)
10. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
11. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and metaanalysis. PLoS One 2009; 4: e6914.
12. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411. Geneva, World Health Organization, 2009.
13. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
14. Rieder HL. Interventions for Tuberculosis Control and Elimination. Paris, International Union Against Tuberculosis and Lung Disease, 2002.
15. Steffen R, Menzies D, Oxlade O, et al. Patients' costs and cost-effectiveness of tuberculosis in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One 2010; 5: e14014.
16. Balabanova Y, Drobniewski F, Nikolayevskyy V, et al. An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 2009; 4: e7129.
17. United Nations Statistics Division. United Nations Common Database. Web Database 2007.
18. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, World Health Organization, 2002.
19. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB). Policy Statement. Geneva, World Health Organization, 2008.
20. Noncommercial Culture and Drug-Susceptibility Testing Methods for Screening Patients at Risk for Multidrug-Resistant Tuberculosis. Policy Statement. WHO/HTM/TB/2011.9. Geneva, World Health Organization, 2011.
21. Roadmap for Rolling Out Xpert MTB-RIF for Rapid Diagnosis of TB and MDR-TB. Geneva, World Health Organization, Stop TB Partnership, 2010.
22. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
23. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-1550. (Pubitemid 44547806)
24. Minion J, Leung E, Menzies D, et al. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 688-698.
25. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
26. Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 2008; 47: 487-495.
27. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751.
28. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
29. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test: Technical and Operational "How-To" Practical Considerations. WHO/HTM/TB/2011.2. Geneva, World Health Organization, 2011.
30. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.